scholarly journals Biological variation of serum neuron-specific enolase and carbohydrate antigen 724 tumor markers

2017 ◽  
Vol 32 (4) ◽  
pp. e22327 ◽  
Author(s):  
Shuo Wang ◽  
Min Zhao ◽  
Runqing Mu ◽  
Xin Zhang ◽  
Ke Yun ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Neuron Specific Enolase ◽  
Carbohydrate Antigen ◽  
Biological Variation ◽  
Serum Neuron Specific Enolase

Tumor Markers in Patients with Chronic Renal Failure

1990 ◽  
Vol 5 (2) ◽  
pp. 85-88 ◽  
Author(s):  
X. Filella ◽  
A. Cases ◽  
R. Molina ◽  
J. Jo ◽  
J.L. Bedini ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Tumor Markers ◽  
Specific Antigen ◽  
Neuron Specific Enolase ◽  
Serum Levels ◽  
Carbohydrate Antigen ◽  
Ca 125 ◽  
Renal Metabolism ◽  
Ca 50

In order to evaluate the specificity of tumor markers in chronic renal failure, we have determined serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), carbohydrate antigen 50 (CA 50), alfafetoprotein (AFP), neuron-specific enolase (NSE), prostatic acid phosphatase (PAP), prostatic specific antigen (PSA), squamous cell carcinoma antigen (SCC), carbohydrate antigen 15.3 (CA 15.3) and carbohydrate antigen 125 (CA 125) in 30 patients with cronic renal failure and in 36 hemodialyzed patients without clinical evidence of neoplasia. CEA, CA 50, NSE and SCC frequently show increased serum levels, suggesting a renal metabolism, while others remain, generally, within the normal levels.

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and α-Fetoprotein

1986 ◽  
Vol 6 (6) ◽  
pp. 458-463 ◽  
Author(s):  
Natale G. DeSanto ◽  
Saturnina Veneroso ◽  
Giuseppe Capodicasa ◽  
Antonello Crisci ◽  
Carmelo Giordano
Keyword(s):  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Neuron Specific Enolase ◽  
Carbohydrate Antigen ◽  
Alpha Fetoprotein ◽  
Ca 50

scholarly journals Biological Variation and Reference Change Value Data for Serum Neuron-Specific Enolase in a Turkish Population

2016 ◽  
Vol 30 (6) ◽  
pp. 1081-1085 ◽  
Author(s):  
Selcuk Matyar ◽  
Ozlem Goruroglu Ozturk ◽  
Esin Ziyanoglu Karacor ◽  
Sedefgul Yuzbasioglu Ariyurek ◽  
Gulhan Sahin ◽  
...  
Keyword(s):  
Neuron Specific Enolase ◽  
Turkish Population ◽  
Biological Variation ◽  
Reference Change Value ◽  
Serum Neuron Specific Enolase

Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase

2013 ◽  
Vol 46 (1-2) ◽  
pp. 148-151 ◽  
Author(s):  
Federica Braga ◽  
Simona Ferraro ◽  
Roberta Mozzi ◽  
Alberto Dolci ◽  
Mauro Panteghini
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Markers ◽  
Chromogranin A ◽  
Neuron Specific Enolase ◽  
Biological Variation

SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER

The Lancet ◽  
1982 ◽  
Vol 319 (8272) ◽  
pp. 583-585 ◽  
Author(s):  
DesmondN Carney ◽  
DanielC Ihde ◽  
MartinH Cohen ◽  
PaulJ Marangos ◽  
PaulA Bunn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Response To Therapy ◽  
Small Cell Lung ◽  
Disease Extent ◽  
Serum Neuron Specific Enolase

Serum neuron-specific enolase levels do not increase after electroconvulsive therapy

1997 ◽  
Vol 150 (2) ◽  
pp. 173-176 ◽  
Author(s):  
Jörg Berrouschot ◽  
Kathrin Rolle ◽  
Hans-Jürgen Kühn ◽  
Dietmar Schneider
Keyword(s):  
Electroconvulsive Therapy ◽  
Neuron Specific Enolase ◽  
Serum Neuron Specific Enolase

Evaluation of serum neuron specific enolase levels among patients with primary and secondary burning mouth syndrome

Cephalalgia ◽  
2021 ◽  
pp. 033310242110466
Author(s):  
Jaimala Kishore ◽  
Fouzia Shaikh ◽  
Adnan Mustafa Zubairi ◽  
Sana Mirza ◽  
Montaser N Alqutub ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Spinal Cord Injuries ◽  
Clinical Symptoms ◽  
Neuron Specific Enolase ◽  
Burning Mouth Syndrome ◽  
Enzyme Linked Immunosorbent Assay ◽  
Painful Condition ◽  
Burning Mouth ◽  
A Minor ◽  
Serum Neuron Specific Enolase

Introduction Burning mouth syndrome is a painful condition of the oral cavity with ambiguous pathogenesis and diagnosis. Neuron-specific enolase is increased in several conditions including peripheral neuropathy of diabetes, ophthalmopathies, spinal cord injuries and tumors. Evidence on association of burning mouth syndrome and neuron-specific enolase is limited. Aim This study aims to evaluate neuron-specific enolase levels in primary and secondary burning mouth syndrome patients and compare the levels of neuron-specific enolase with associated conditions in secondary burning mouth syndrome. Methods One hundred and twenty-eight patients of more than 18 years of age with no gender predilection and having clinical symptoms of burning mouth syndrome and 135 healthy subjects were included. All the patients fulfilled Scala’s criteria for the diagnosis of burning mouth syndrome, including “primary” (idiopathic) and “secondary” (resulting from identified precipitating factors) burning mouth syndrome patients. Blood samples were obtained from burning mouth syndrome patients. Serum neuron-specific enolase was evaluated using enzyme-linked immunosorbent assay. To compare means and standard deviations, among primary and secondary burning mouth syndrome, data was analysed with analysis of variance and multiple comparisons test. Results The mean age of the study participants for burning mouth syndrome and healthy subjects was 53.30 and 51.6 years, respectively. Amongst the secondary burning mouth syndrome group, 32 (25%) of the patients had menopause, 15 (11.7%) had diabetes, eight (6.2%) of the patients had nutritional deficiency, seven (5.4%) had combined diabetes, menopause, and depression, six (4.6%) had combined diabetes and depression, four (3.1%) were diagnosed with Sjögren’s syndrome. A minor percentage of 2.3% (three) had gastroesophageal reflux disease, while the remaining three (2.3%) patients in the secondary burning mouth syndrome group were on anti-depressants. There was a statistically significant increase in the levels of neuron-specific enolase in primary burning mouth syndrome as compared to the secondary burning mouth syndrome and healthy groups. Among the subgroups of secondary burning mouth syndrome, diabetic individuals showed a significant increase in neuron-specific enolase level when compared with other conditions in the secondary burning mouth syndrome patients. Discussion and conclusion: The raised serum neuron-specific enolase levels in patients suffering from primary burning mouth syndrome highlight a possible neuropathic mechanism. It was also increased in the sub-group of secondary burning mouth syndrome patients having diabetes. Although it cannot be ascertained whether the deranged values in the diabetic group were due to burning mouth syndrome or due to diabetes, the raised quantity of neuron-specific enolase in the primary burning mouth syndrome group is a reliable diagnostic indicator. Future studies on the assessment of neuron-specific enolase levels as a diagnostic tool for onset and management of primary and secondary burning mouth syndrome are recommended.

scholarly journals Serum neuron-specific enolase, a marker of neuronal injury, increases after catheter ablation of atrial fibrillation

2018 ◽  
Vol 46 (11) ◽  
pp. 4518-4526 ◽  
Author(s):  
Aynur Acibuca ◽  
Veysel Kutay Vurgun ◽  
Demet Menekse Gerede ◽  
Ali Timucin Altin ◽  
Inci Sule Gul ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Neuron Specific Enolase ◽  
Clinical Importance ◽  
Neuronal Injury ◽  
Neurological Deficits ◽  
Reference Limit ◽  
Before And After ◽  
Upper Reference Limit ◽  
Serum Neuron Specific Enolase

Objective Catheter ablation of atrial fibrillation (AF) can lead to thromboembolic complications, especially stroke. We measured the periprocedural serum neuron-specific enolase (NSE) level, which is a biomarker of neuronal injury, after ablation of AF. Methods Forty-three patients with paroxysmal AF were prospectively enrolled before radiofrequency ablation. A neurological examination was performed before and after the procedure. The serum NSE level was determined before and at the end of the procedure and at 2, 24, and 48 h after the procedure. Results No patients developed new neurological deficits. However, the median (interquartile range) NSE level increased after ablation from 6.7 (3.87) ng/mL at baseline to 11.48 (5.3) ng/mL at 24 h postoperatively. The NSE level exceed the upper reference limit of normal (17 ng/mL) in 14 patients (33%), and these patients were found to have a larger left atrium. Conclusions Serum NSE increased in most of the patients undergoing ablation for AF, and it exceeded the normal limit in one-third of the patients. Although NSE is a biomarker of neuronal injury, the clinical importance of this increase after AF ablation and its relationship with the left atrial diameter should be evaluated in a longitudinal study.

Sign in / Sign up

Export Citation Format

Share Document